A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers

Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP Jr, Taylor EL, Robson MC · Journal of Vascular Surgery

Silver sulfadiazine reduced ulcer size significantly more than either the copper-tripeptide cream or placebo, and the copper-tripeptide cream did not differ from placebo. This is the largest randomised human wound trial of GHK-Cu and it is null.

Population

86 evaluable patients with chronic venous stasis ulcers

Intervention

0.4% tripeptide-copper complex cream

Comparator

1% silver sulfadiazine cream and an inert vehicle placebo

Limitations

Topical 0.4% cream on chronic ulcers; single indication, and the trial's design question was silver sulfadiazine rather than the copper tripeptide. Evaluator-blinded, not double-blind.